Motexafin gadolinium

{{Short description|Chemical compound}}

{{Drugbox

| verifiedrevid = 447766566

| IUPAC_name =

| image =

| image2 = Motexafin gadolinium 3D sticks.png

| tradename =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category =

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status =

| routes_of_administration =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| CAS_number_Ref = {{cascite|correct|??}}

| CAS_number = 156436-89-4

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = 6433A42F4F

| ATC_prefix = none

| ATC_suffix =

| ATC_supplemental =

| PubChem = 158385

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank =

| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}

| ChemSpiderID = 139341

| KEGG_Ref = {{keggcite|correct|kegg}}

| KEGG = D05080

| ChEBI_Ref = {{ebicite|correct|EBI}}

| ChEBI = 50161

| chemical_formula =

| C=52 | H=72 | Gd=1 | N=5 | O=14

| smiles = CCC1=C(C2=CC3=NC(=CN=C4C=C(C(=CC4=NC=C5C(=C(C(=N5)C=C1[N-]2)CCCO)C)OCCOCCOCCOC)OCCOCCOCCOC)C(=C3CCCO)C)CC.CC(=O)[O-].CC(=O)[O-].[Gd+3]

| StdInChI_Ref = {{stdinchicite|correct|chemspider}}

| StdInChI = 1S/C48H66N5O10.2C2H4O2.Gd/c1-7-35-36(8-2)40-28-42-38(12-10-14-55)34(4)46(53-42)32-50-44-30-48(63-26-24-61-22-20-59-18-16-57-6)47(62-25-23-60-21-19-58-17-15-56-5)29-43(44)49-31-45-33(3)37(11-9-13-54)41(52-45)27-39(35)51-40;2*1-2(3)4;/h27-32,54-55H,7-26H2,1-6H3;2*1H3,(H,3,4);/q-1;;;+3/p-2/b39-27-,40-28-,41-27-,42-28-,45-31-,46-32-,49-31+,49-43+,50-32+,50-44+;;;

| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}

| StdInChIKey = VAZLWPAHMORDGR-WRIGXHCHSA-L

}}

Motexafin gadolinium (proposed tradename Xcytrin) is an inhibitor of thioredoxin reductase and ribonucleotide reductase. It has been proposed as a possible chemotherapeutic agent in the treatment of brain metastases.{{cite journal |vauthors=Richards G, Mehta M |title=Motexafin gadolinium in the treatment of brain metastases |journal=Expert Opinion on Pharmacotherapy |volume=8 |issue=3 |pages=351–9 |year=2007 |pmid=17266469 |doi=10.1517/14656566.8.3.351|s2cid=25542776 }}